The FDA quietly made public an analysis finding no child deaths were definitively linked to COVID-19 vaccines after reviewing 96 VAERS reports through Aug. 14, 2025, undercutting former FDA vaccine chief Dr. Vinay Prasad’s claim that at least 10 previously unreported deaths were caused by the shots. For clinicians, the report reinforces a key practice point: post-vaccination adverse event reports can signal risk, but they do not establish causality, even as myocarditis remains a labeled rare complication to monitor in teen boys and young men.

The Move

• The agency’s Dec. 5 analysis, surfaced in a letter from Sen. Ron Johnson to HHS Secretary Robert F. Kennedy Jr., reviewed 96 reports of pediatric deaths submitted to VAERS.

• FDA investigators found zero cases that were “certain” to be caused by COVID-19 vaccination.

• They classified five deaths as “possible” and two as “probable,” while explicitly noting those categories do not prove causation and that alternative explanations could not be ruled out.

• The findings conflict with Prasad’s earlier memo stating children died “after and because of receiving” the COVID shot.

Why it Matters for Care

• At the bedside, this is a reminder to distinguish temporal association from causal attribution when counseling families about vaccine safety.

• Myocarditis remains the main serious adverse event discussed here, especially in adolescent boys and young men, and FDA had already instructed Pfizer and Moderna to update COVID-19 vaccine labels on that risk.

• Clinicians should continue to evaluate chest pain, dyspnea, palpitations, or syncope after vaccination promptly, while also remembering that viral infections — including COVID-19 itself — are a more common cause of myocarditis.

• Mild myocarditis often resolves with rest and monitoring; severe cases can require hospitalization.

Between the Lines

• This is as much about health-policy credibility as vaccine safety: Prasad’s unsupported claim was used to help justify proposed changes to how FDA reviews vaccines.

• The report underscores the limits of VAERS, a passive surveillance system open to reports from anyone and not designed on its own to determine causality.

• Politically, the document landed via a transparency push from Johnson to Kennedy, highlighting how vaccine surveillance data are being pulled into broader fights over federal public health authority.

• For clinicians, the second-order effect is familiar: public overreading of safety signals can complicate informed consent, fuel hesitancy, and lengthen already difficult conversations with parents.

What to Watch

• Whether HHS or FDA publicly clarifies how this analysis should shape future COVID-19 vaccine review standards.

• Whether lawmakers press for additional document releases, hearings, or changes to vaccine safety surveillance and transparency rules.

• Whether updated federal messaging alters uptake, especially in pediatric and adolescent vaccination.

• Whether any further FDA analyses refine the myocarditis risk discussion or identify stronger methods than VAERS-based review for rare-event assessment.

Source: NBC News Health